LPS produced by intestinal Gram-negative bacteria is a key molecule in the early development of inflammation and metabolic diseases and has an endotoxin effect, inducing macrophage activation (Wellen and Hotamisligil, 2005), which leads to increases in serum TNF-α and interleukin 6 (IL-6) and triggers IR, which in turn leads to excessive ROS production in the gastrointestinal system (Gyuraszova et al., 2017). Here, IL6 is linked to metabolic disease.